Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE) Revenue
Annual & quarterly revenue history · segment & region breakdown
SYRE · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsSpyre Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.09B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
Compare revenue vs peers
BiotechnologyCompare SYRE revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Spyre Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Spyre Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Spyre Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
SYRE revenue · 4 questionsSYRE's trailing twelve-month (TTM) revenue is $0.09B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Spyre Therapeutics, Inc. SEC filings · GAAP · Spyre Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026